This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).
Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases.
RhAPPcast: A Case-Based Approach to Early Intervention and Renal Preservation in Lupus Nephritis
Stay up to date with the latest guidance in lupus nephritis management in this RhAPPcast episode featuring host Amanda Mixon, PA-C, and Tiffany Terrell, FNP-C. Through a practical case-based discussion, they explore how the latest American College of Rheumatology (ACR) guidelines can be applied in real-world clinical practice to support early detection, timely intervention, and long-term kidney preservation in patients with lupus nephritis.
Learn about current recommendations for screening and monitoring patients with systemic lupus erythematosus (SLE), the role of kidney biopsy in diagnosis, and evolving treatment strategies for lupus nephritis. The discussion highlights guideline-directed approaches to therapy selection, treatment monitoring, response assessment, and management of refractory disease, while emphasizing the importance of preserving renal function and improving long-term outcomes.
Whether you're a rheumatology provider, advanced practice provider (APP), or healthcare professional caring for patients with lupus, this episode provides practical insights into translating clinical guidelines into everyday practice and optimizing care for patients with lupus nephritis. For more expert-led education, visit the Content Rheum and download the RhAPP Ace app to stay up to date with the latest clinical insights in rheumatologic care.
31 Oct 2026
RhAPPcast: Introducing the RhAPP Advocacy Program
In this special edition of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers (RhAPP), Heather Finlayson and Kevin Daley discuss rheumatology advocacy and the importance of strengthening the APP voice in healthcare policy. They introduce the RhAPP Advocacy Committee and explore how nurse practitioners, physician assistants, and pharmacists can get involved in addressing insurance barriers, supporting medication access, and advocating for their patients and practices.
This episode highlights key advocacy issues in rheumatology, including step therapy, non-medical switching, prior authorization, prescription drug affordability boards (PDABs), and the federal 340B Drug Pricing Program. Heather and Kevin discuss how insurance requirements and policy decisions intersect with everyday patient care, sharing practical ways clinicians can participate through legislative outreach, letter writing, virtual testimony, and patient education. The conversation also explores payer advocacy and the importance of bringing clinical experiences and patient perspectives into state and federal policy discussions.
Designed for rheumatology APPs and other healthcare professionals, this discussion outlines the committee’s plans for regional leadership, virtual meetings, and ongoing advocacy education. Whether you are new to healthcare advocacy or looking for ways to become more involved, this episode offers an approachable starting point for making your voice heard and helping patients do the same. For more rheumatology education and podcasts, visit RhAPP’s website and explore the RhAPP ACE app.
29 Oct 2026
FAQ: How Does Combination Therapy of Guselkumab and Golimumab Work in PsA?
In this FAQ video module, William Saalfeld, NP, explains the rationale for investigational combination therapy with guselkumab and golimumab in psoriatic arthritis (PsA). He reviews how guselkumab targets interleukin-23 (IL-23) and golimumab inhibits tumor necrosis factor (TNF), highlighting how these medications address complementary inflammatory pathways involved in immune activation, synovitis, and joint inflammation.
This episode examines the phase 2a AFFINITY study, which compared guselkumab plus golimumab with guselkumab monotherapy. William discusses the primary endpoint of minimal disease activity (MDA), American College of Rheumatology (ACR) response measures, and exploratory findings in patients with elevated C-reactive protein (CRP). He explains that the primary endpoint was not met, while secondary and exploratory analyses suggested potential additional benefits in peripheral joint disease and physical function. The discussion also considers why improvements in psoriasis, enthesitis, and dactylitis did not show a clear additional benefit with combination therapy.
Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other healthcare professionals, this FAQ offers a concise overview of dual IL-23 and TNF inhibition in psoriatic arthritis. William emphasizes that guselkumab plus golimumab remains investigational, with further research needed to clarify which patients may benefit and its potential role in future PsA treatment strategies. For more expert-led education, visit the Content Rheum and download the RhAPP Ace app to stay up to date with the latest clinical insights in rheumatologic care.
Who has been a guest on RhAPPcast
Names identified in recent episode analyses. Showing up to five guests.
Danielle Gatti-Palumbo
Jennifer Mylod
Kyle George
Danielle Gatti Palumbo
Laura Bush
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
5 ratings
Spotify
5.0 / 5
4 ratings
Podcast Authority Score: 49 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
86
Social presence
0
YouTube
0
Engagement
32
Contact RhAPPcast
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
